Maggie A. Pax has served as a director of Repligen since March 2024. Ms. Pax brings over 25 years of experience leading the development and execution of growth strategies for global companies. This includes eight years with Thermo Fisher, where, from 2016 to 2020, she served as Vice President, Strategy and Innovation for the clinical supply chain business. In this role, she led strategic planning, developed customer-facing innovation programs, and drove the business case for the company’s multi-billion acquisition of Patheon, a leading biopharmaceutical contract manufacturer. Ms. Pax’s background also includes her position as Senior Director, Corporate Development & Strategy at Thermo Fisher from 2013 to 2016, where she led post-merger commercial integration for the company’s acquisition of Life Technologies. Earlier in her career with Thermo Fisher, she was the Senior Director, Portable Analytical Instrumentation from 2012 to 2013. From 1989 to 2000, Ms. Pax was with Phillips Healthcare (“Phillips”), a leading medical device company, where she held senior leadership roles in Business Development, Marketing and Product Management. Between her Phillips and Thermo Fisher roles, Ms. Pax held several entrepreneurial leadership positions, including as Vice President, Business and Clinical Development for five years (2006 to 2011) with Microchips Biomedical, an MIT startup company that was acquired by Daré Bioscience. Ms. Pax is currently an independent board director Alimera Sciences, a Nasdaq-listed pharmaceutical company, and Jellagen, a privately-held UK company. She also sits on the board of the U.S. subsidiary of BioPorto A/S, a Danish-based kidney biomarker company. Ms. Pax advises a range of healthcare and life sciences companies on business strategy, commercial growth, and partnerships. She holds a B.A. from the College of Holy Cross, and an M.B.A. from Harvard Business School, where she currently serves as a board member of the Harvard Business School Healthcare Alumni Association.
What is Margaret Pax's net worth?
The estimated net worth of Margaret Pax is at least $148,053.85 as of March 17th, 2025. Ms. Pax owns 1,043 shares of Repligen stock worth more than $148,054 as of March 26th. This net worth estimate does not reflect any other assets that Ms. Pax may own. Learn More about Margaret Pax's net worth.
How do I contact Margaret Pax?
The corporate mailing address for Ms. Pax and other Repligen executives is 41 SEYON STREET BUILDING 1 SUITE 100, WALTHAM MA, 02453. Repligen can also be reached via phone at (781) 250-0111 and via email at investors@repligen.com. Learn More on Margaret Pax's contact information.
Has Margaret Pax been buying or selling shares of Repligen?
During the last ninety days, Margaret Pax has bought $37,672.50 of Repligen stock. Most recently, on Monday, March 17th, Margaret Pax bought 250 shares of Repligen stock. The stock was acquired at an average cost of $150.69 per share, with a total value of $37,672.50. Following the completion of the transaction, the director now directly owns 1,043 shares of the company's stock, valued at $157,169.67. Learn More on Margaret Pax's trading history.
Who are Repligen's active insiders?
Repligen's insider roster includes Nicolas Barthelemy (Director), James Bylund (SVP), Karen Dawes (Director), Carrie Eglinton Manner (Director), Christine Gebski (Insider), Anthony Hunt (Executive Chair), Ralf Kuriyel (VP), Martin Madaus (Director), Margaret Pax (Director), Thomas Ryan, Jr. (Director), and Jon Snodgres (CFO). Learn More on Repligen's active insiders.
Are insiders buying or selling shares of Repligen?
In the last year, Repligen insiders bought shares 3 times. They purchased a total of 3,865 shares worth more than $487,610.60. In the last year, insiders at the biotechnology company sold shares 3 times. They sold a total of 46,728 shares worth more than $7,342,936.94. The most recent insider tranaction occured on March, 17th when Director Margaret Pax bought 250 shares worth more than $37,672.50. Insiders at Repligen own 1.2% of the company.
Learn More about insider trades at Repligen. Information on this page was last updated on 3/17/2025.
